



1A Main Street  
Sparta, NJ 07871

website: [www.acceptys.com](http://www.acceptys.com)

### **Acceptys and Seattle Biomedical Research Institute Join in Fight Against Malaria**

**January 31, 2008** Acceptys, Inc. announced today collaboration with Seattle Biomedical Research Institute (SBRI) focused on the development of vaccines and antibody-based therapies against malaria.

Every year, malaria is estimated to kill between 1.5 million and 2.7 million people and malaria parasites infect 300 million to 500 million new victims, primarily in Africa. The Acceptys/SBRI program will be incorporated within SBRI's overall anti-malaria effort, the goal of which is to improve available and develop new alternatives to address this significantly unmet medical need.

Under the collaboration, SBRI and its researchers have been given access to Acceptys proprietary technology platform, which uniquely allows for the effective capture and production of natural human antibodies from targeted patient populations that have been exposed to an infectious pathogen. SBRI will deploy the Acceptys technology to capture natural human antibodies from malaria resistant patients in order to gain insight into how the human body effectively fights the disease. The work will take place primarily in SBRI's research and development facilities and be supported by SBRI funding.

"There have been studies in which scientists have taken antibody-rich blood plasma from malaria-immune Africans, injected the blood plasma into people who had no immunity to malaria, and effectively transferred the protection," said Dr. Patrick Duffy, Director of SBRI's malaria program. "We plan to capture the antibodies generated by those malaria-immune patients, and study the captured human antibodies' activities in order to help us better understand how to develop a vaccine that will effectively provide protection against malaria in the broader population. The Acceptys technology provides us the unique ability to effectively capture and produce those important anti-malarial human antibodies."

Acceptys will develop the human antibodies captured as potential treatments for patients who have become ill with malaria and for whom a vaccine would not be beneficial. "We are pleased to collaborate with SBRI in their effort to develop an effective vaccine for malaria, which someday could benefit millions of people worldwide who are regularly exposed to this deadly disease", said Kris Blader, President of Acceptys. "The development of the vaccine is of course the top priority. It is an added benefit to Acceptys to be able to use this work to develop antibody-based treatments for patients already ill with malaria. This collaboration is also a great example of how public-private partnerships can help overcome critical health problems in Africa and around the world."

#### **For more information:**

Kris Blader  
President, Acceptys, Inc.  
U.S. Phone: 973-729-7779

#### About Acceptys

Acceptys is a biotechnology company focused on the commercialization of its proprietary platform technologies for the capture, production and development of natural human antibodies as therapies for infectious disease. Acceptys has a number of programs in progress, including natural human antibody programs focused on pneumonia, Hepatitis C and malaria. [www.acceptys.com](http://www.acceptys.com). Acceptys is affiliated with Patrys Limited (ASX: PAB), an Australia publicly listed company focused on the development of natural human antibodies for cancer and other major indications. [www.patrys.com](http://www.patrys.com).

#### About SBRI

SBRI discoveries advance global health. Its infectious disease research is the foundation for new drugs, vaccines and diagnostics that benefit those who need help most: the 14 million who will otherwise die each year from infectious diseases. A non-profit organization founded in 1976, SBRI has nearly 250 staff members working in research labs in Seattle and field labs in Tanzania. By partnering with key collaborators around the globe, SBRI ensures that its discoveries will save lives sooner. [www.sbri.org](http://www.sbri.org)